54gene’s Series B, Vilsquare’s founder’s journey
On Thursday, September 16, 2021, African genomics research startup 54gene, announced a $25 million Series B round.
The funding will be used to expand the startup’s sequencing, target identification and validation, and precision medicine clinical trial capabilities, enabling drug discovery in Africa for Africans and the world.Advertisement
Cathay AfricInvest Innovation Fund led the round. Existing investors like Adjuvant Capital, KdT Ventures, Plexo Capital, Endeavor Capital, and Ingressive Capital participated in the round.
Launched in 2019 by Dr Abasi Ene-Obong (CEO), 54gene is a healthtech company centred around unlocking scientific discoveries and enhancing diagnosis and treatment outcomes across Africa and the rest of the world. Continue reading
Image: techpoint.africa
The new CAMON 18 Premier brings together the best of the CAMON series, such as…
South Africa’s communications minister said today that this week’s massive social media outage of Facebook…
At the first Google for Africa event held today, October 6, 2021, global Internet giant,…
On Thursday, July 22, 2021, the Central Bank of Nigeria (CBN) revealed that the pilot…
FNB South Africa, one of the country’s top lenders, has announced today the launch of…
Google plans to invest up to $50 million in African early and growth-stage startups via…